NeuroPace Inc (NPCE) — Titan Protect Analysis

NPCE

NeuroPace Inc

Healthcare · ·

$15.74

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$550M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-54.23

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.0%

Year-over-year revenue change

Profit Margin

-21.7%

How much profit the company keeps from each dollar of revenue

ROE

-111.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+27% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About NeuroPace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for

https://www.neuropace.com

Country: United States Employees: 220 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.996

Good returns relative to risk taken

Kelly Fraction

0.0741

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.072

Returns exceed worst-case losses — strong risk profile

Annual Return

58.4%

Historical annualised return based on price data

Max Drawdown

-54.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.93

Significantly more volatile than the market

52W High

$19.60

20% below the year high

52W Low

$7.56

108% above the year low

Avg Volume

209,566

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.65

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

487.49

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

78.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-25.2%

Profit from core operations before interest and tax

Free Cash Flow

$-2,739,000

Negative — the business is spending more than it generates

Revenue (TTM)

$100M

Total revenue over the last 12 months

Net Income

$-21,565,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$20.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go